Cipla (CIPLA) Q3 24/25 earnings summary

Executive summary

• Achieved record quarterly revenue and EBITDA margin, with strong growth in India, North America, South Africa, and EMEU markets.

• Maintained leadership in chronic therapies in India, expanded innovative product offerings, and advanced ESG initiatives, including Zero Waste to Landfill certification.

• Unaudited consolidated and standalone financial results for the quarter and nine months ended 31 December 2024 were approved and released.

Financial highlights

• Quarterly revenue reached INR 7,073 crore (₹7,072.97 crore), up 8.1% year-on-year; EBITDA at INR 1,989 crore, margin at 28.1%, and net profit at INR 1,574.59 crore.

• PAT margin at 22.2% (up 617 bps year-over-year); effective tax rate at 25.5% after adjustments.

• Net cash position stood at INR 8,947 crore; total debt including lease liability at INR 466 crore as of December 31, 2024.

• R&D spend was INR 360 crore, 5.1% of revenue.

• Other income for the quarter included ₹67 crore from a one-time legal settlement.

Outlook and guidance

• Retains guidance for top-line growth in FY26, with further profitability guidance to follow post-budget finalization.

• EBITDA for FY25 expected to exceed earlier guidance of 24.5%-25.5%.

• Launch of generic Advair planned for H1 FY26; Abraxane launch expected in Q4 FY26, pending regulatory approval.

• Focus on innovative launches, expanding differentiated assets in North America, and continued ESG commitment.

• The company expects a favorable outcome in ongoing litigation with the National Pharmaceutical Pricing Authority and has not made provisions for related demand notices.